Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Hepion Pharmaceuticals, Inc.Financial_Report.xls
10-Q - 10-Q - Hepion Pharmaceuticals, Inc.a13-23001_110q.htm
EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc.a13-23001_1ex31d1.htm
EX-31.2 - EX-31.2 - Hepion Pharmaceuticals, Inc.a13-23001_1ex31d2.htm
EX-32.2 - EX-32.2 - Hepion Pharmaceuticals, Inc.a13-23001_1ex32d2.htm
EX-10.1 - EX-10.1 - Hepion Pharmaceuticals, Inc.a13-23001_1ex10d1.htm

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
CONTRAVIR PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2013
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I am the Chief Executive Officer of ContraVir Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended September  30, 2013 and filed with the Securities and Exchange Commission (“Form 10-Q”).

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 19, 2013

/s/ GARY S. JACOB

 

Gary S. Jacob

 

President and Chief Executive Officer